These studies will test our hypothesis that a state independent, genetically influenced increase in muscarinic supersensitivity exists in patients with major affective illness. Two different methods will be used: (1) The cholinergic REM Induction Test (CRIT). In this test, the latency is measured to the onset of REM sleep following an infusion of either placebo or arecoline, a muscarinic agonist, during the second NREM period. (2) Direct measurements of muscarinic receptors, utilizing tritriated quinichidinyl benzilate (3H-QNB), on fibroblasts grown from a skin biopsy. Both methods will be used to study the following groups of subjects: (1) euthymic, unmedicated patients with bipolar and unipolar affective illness, as well as normal controls. (2) Male students and nonacademic staff at UCSD who have been identified as being at risk for affective illness on the basis of a prior history of affective illness, a family history of affective illness, or both. Control subjects with neither a personal nor a family history will be studied. (3) First degree family members of patients with affective illness and family members with and without a personal history of affective illness will be compared with each other and with the proband, who has a short response latency on the CRIT. These studies will address the following questions: (1) Is the response on the CRIT correlated with QNB estimates of muscarinic receptor binding on fibroblasts? (2) Can we replicate our earlier findings that the CRIT identifies euthymic patients with bipolar illness, and extend it to unipolar patients? (3) Can we replicate the preliminary findings of Nadi et al (in press) that muscarinic receptor binding is elevated in patients with affective illness and their first degree relatives? (4) Can either or both of these methods be used as a marker of vulnerability for affective illness? In addition, we wish to explore the possibility of using the CRIT during daytime sleep studies. If it were shown that this were feasible, it would increase the utility of the method. These studies offer new ways of assessing vulnerability and pathophysiological mechanisms in patients with affective illness, with theoretical and clinical implications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH038738-02
Application #
3376853
Study Section
(PCBB)
Project Start
1984-04-01
Project End
1987-03-31
Budget Start
1985-04-01
Budget End
1986-03-31
Support Year
2
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
Schools of Medicine
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Landolt, Hans-Peter; Kelsoe, John R; Rapaport, Marc H et al. (2003) Rapid tryptophan depletion reverses phenelzine-induced suppression of REM sleep. J Sleep Res 12:13-8
Landolt, Hans-Peter; Gillin, J Christian (2002) Different effects of phenelzine treatment on EEG topography in waking and sleep in depressed patients. Neuropsychopharmacology 27:462-9
Landolt, H P; Raimo, E B; Schnierow, B J et al. (2001) Sleep and sleep electroencephalogram in depressed patients treated with phenelzine. Arch Gen Psychiatry 58:268-76
Landolt, H P; Gillin, J C (2001) Sleep abnormalities during abstinence in alcohol-dependent patients. Aetiology and management. CNS Drugs 15:413-25
Landolt, H P; de Boer, L P (2001) Effect of chronic phenelzine treatment on REM sleep: report of three patients. Neuropsychopharmacology 25:S63-7
Gottschalk, L A; Fronczek, J; Abel, L et al. (2001) The cerebral neurobiology of anxiety, anxiety displacement, and anxiety denial. Psychother Psychosom 70:17-24
Drummond, S P; Gillin, J C; Smith, T L et al. (1998) The sleep of abstinent pure primary alcoholic patients: natural course and relationship to relapse. Alcohol Clin Exp Res 22:1796-802
Dow, B M; Kelsoe Jr, J R; Gillin, J C (1996) Sleep and dreams in Vietnam PTSD and depression. Biol Psychiatry 39:42-50
Gillin, J C; Buchsbaum, M S; Valladares-Neto, D C et al. (1996) Effects of zolpidem on local cerebral glucose metabolism during non-REM sleep in normal volunteers: a positron emission tomography study. Neuropsychopharmacology 15:302-13
Seifritz, E; Moore, P; Trachsel, L et al. (1996) The 5-HT1A agonist ipsapirone enhances EEG slow wave activity in human sleep and produces a power spectrum similar to 5-HT2 blockade. Neurosci Lett 209:41-4

Showing the most recent 10 out of 51 publications